Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Biol Rep. 2018 Nov 20;46(1):1393–1400. doi: 10.1007/s11033-018-4488-x

Table 1.

Inhibitors of the Angiogenesis Pathway

Inhibitor Cell Type Process Inhibited Pathway Reference
Stigmatellin WT cybrids; in vitro Inhibits HIF-1α stabilization and accumulation Binding to Qo site inhibits mROS production [17]
Terpestacin in vivo Murine FM3A breast cancer cells; in vivo Inhibits tumor angiogenesis Inhibition of HIF-1α Mediated VEGF expression [27]
Terpestacin in vitro Human HT1080 fibrosarcoma cells, HUVECs; in vitro Inhibits VEGF production; inhibits tube formation and angiogenesis by HUVECs Decreases mROS levels by inhibiting UQCRB which inhibits HIF-1α stabilization and accumulation, inhibiting VEGF production [27]
Uqcrb-MO Zebrafish embryos Inhibits VEGF production Gene knockdown of uqcrb gene leads to decreased expression of vegfa gene [28]
siUQCRB HUVECs; in vitro Inhibits endothelial cell invasiveness through inhibition of ERK and Akt pathways Gene knockdown of uqcrb leads to decreased mROS levels, decreased activation of VEGFR2 [29]
Rotenone and thenoyltrifluoroacetone (TTFA) Cardiomyocytes; in vitro Inhibits mROS production Inhibits formation of ubiquinol by preventing transfer of electrons from Complex I and Complex II [40]
Matairesinol HUVECs; in vitro and in vivo Inhibits HUVEC tube formation Inhibits mROS production which decreases HIF-1α stabilization and VEGF production [74]
GPX1 and catalase A549 adenocarcinomic human alveolar basal epithelial cells; in vitro Inhibits HIF-1α stabilization and survival Breaks down hydrogen peroxide to water which prevents breakdown of prolyl hydroxylase [76]